Biotechnology Investment Trends

She replaced $50 fertilizer with $2 bacteria. Farmers saved $25 billion 🦠🌱 ---------- In the late 1970s, a young Brazilian woman named Mariangela Hungria entered soil science—a field dominated by men who believed fertility came from chemicals. Her Professors told her to choose a different path. She refused. Her idea was simple but radical: instead of expensive synthetic fertilizers, what if we could use naturally occurring bacteria to feed nitrogen to plants? Nitrogen is essential for plant growth. Most farmers buy it in chemical form—expensive, polluting, and often imported. But certain bacteria can pull nitrogen directly from the air and deliver it to plant roots. The problem was getting it to work at scale. Hungria spent four decades perfecting it. She studied rhizobia bacteria that form relationships with legume roots. She found that treating soybean seeds with the right bacterial strains could increase yields by 8% compared to synthetic fertilizers. Then she isolated strains of another bacteria, Azospirillum brasilense, that could boost nitrogen uptake even further. Combining both doubled the yield increase. But she didn't just stay in the lab. She spent as much time in farmers' fields as she did doing research. She held field days, wrote manuals in Portuguese, and convinced skeptical farmers to try her methods. The results? Her microbial treatments are now used on 85% of Brazil's soybean fields—over 40 million hectares. Farmers spend just $2-3 per hectare on bacterial inoculant versus $30-50 on synthetic fertilizer. Brazil's soybean production went from 15 million tons in 1979 to 173 million tons today. The environmental impact is massive: 230 million metric tons of CO2 emissions prevented annually. And because farmers don't need to buy expensive imported fertilizers, they save an estimated $25 billion per year. In 2025, Hungria won the World Food Prize—often called the Nobel Prize of food and agriculture—for her work. https://lnkd.in/gTagmSSU "Replacing the use of chemicals with biologicals in agriculture has been the fight of my life," she said. "I like to say Norman Borlaug made the Green Revolution possible, and we had this great opportunity to start a 'Micro Green Revolution'—but with microorganisms." 📌Sources: Washington Post, World Food Prize Foundation, Down to Earth ✓Read and learn more: https://lnkd.in/gaPgE6C6 https://lnkd.in/gwF3Wiy4 https://lnkd.in/gNWTzwSs https://lnkd.in/gBNQRZKd https://lnkd.in/g4tdwnsw https://lnkd.in/gqYE24Sk https://lnkd.in/gRbyGmfb https://lnkd.in/gia3CWec https://lnkd.in/gvF4HNJv https://lnkd.in/g6g37FUN https://lnkd.in/g9wcCmwW https://lnkd.in/guvH3cvR ✓Peer-Reviewed Scientific Publications: https://lnkd.in/g5YXQBUh https://lnkd.in/gK8rR-hX https://lnkd.in/gnUeHymZ https://lnkd.in/gKNc3AMX ✓Watch this and learn more: https://lnkd.in/gtvzu6eR Credits: CTTO

Probably, one of the largest collaborative efforts in biotech, since the Human Genome Project: the Human Cell Atlas has arrived! 🧬 I think the Human Cell Atlas (HCA) is a pretty monumental leap in systems biology, an international effort involving 3,600 researchers from 102 countries, has released its first draft atlas of human cells. This isn’t just another dataset—this is the blueprint of human biology, built cell by cell, tissue by tissue, organ by organ. The HCA integrated data from 62 million cells, sourced from 9,100 donors, spanning every stage of human development—embryonic to adult. Researchers organized their work into 18 Biological Networks, focusing on key organs like the lung, nervous system, and eye. Some of the tools like single-cell RNA sequencing, spatial transcriptomics, and multi-omics were combined to profile and map cells with unprecedented precision. Notably, Google provided essential cloud infrastructure and AI tools like scTab (for annotation) and SCimilarity (for cell similarity searches), helping researchers handle vast and complex datasets efficiently. It is also important that local scientists and the HCA Ethics Working Group put efforts to make sure data represented populations globally, prioritizing equity and open access. Now, how can we use it, practically speaking? Here I picked some of the key aspects that might be very useful for the biotech community: ✅ Precise Target Discovery: Pinpoint disease-specific cell types and biomarkers to create highly targeted therapies. ✅ Better Disease Models: Build realistic organoids and in vitro models informed by detailed cell maps for accurate drug testing. ✅ Personalized Medicine: Utilize data from diverse populations to design therapies tailored to genetic and environmental variations. ✅ Safer Drugs: Analyze tissue-specific metabolism to predict and avoid adverse drug effects. ✅ AI-Driven Insights: Tap into machine-learning tools like PopV and SCimilarity to accelerate discovery and refine findings. I believe, the Atlas could be a playing ground for other AI tools and new workflows! ✅ Early Diagnosis: Identify subtle gene expression changes for early detection of diseases like cancer or neurodegenerative disorders. If you're in biotech, drug discovery, or systems biology, this resource is now open and available—check it out! Link in the comments 👇 Image source:  Springer Nature

🚨 Regeneron just dropped $3B on U.S. manufacturing: but here’s the twist… it’s not building its own plant. 🚨 Instead, it’s teaming up with CDMO giant FUJIFILM Diosynth Biotechnologies in a 10-year deal to produce commercial biologics at Fujifilm’s massive new site in Holly Springs, NC. 💉 📍 Why this matters: 🔁 This move nearly doubles Regeneron’s U.S. manufacturing capacity 🇺🇸 It's part of the broader pharma shift toward on-shoring, triggered by looming Trump tariffs 🔧 The Fujifilm site (already a $3.2B investment) begins operations this year 💬 Regeneron CEO says: “Every FDA-approved drug we’ve developed came out of our New York labs.” 🧠 The bigger trend? Pharma’s quietly transforming its supply chain. It’s not just about building: it’s about strategic partnerships, resilience, and speed to market. Combine this with Roche’s $50B U.S. expansion, and you’ve got a clear signal: 📢 America is back at the center of global biomanufacturing. Will CDMO partnerships be the new norm? Or will more biotechs follow Eli Lilly, J&J, and Novartis with in-house builds? #Biotech #Pharma #Manufacturing #Onshoring #CDMO #LifeSciences #Regeneron #FujifilmDiosynth #Biologics #Tariffs #SupplyChain #DrugDevelopment #Innovation #HollySprings #PharmaNews #Healthcare

For years, biotech venture capital fueled early innovation, making risky bets, chasing big exits and tolerating long timelines. I grew up in that market but today, we’re witnessing a tectonic shift. VC funding for preclinical biotech is down 60% since 2021. Startups are stalling midstream, Series A rounds are elusive and risk appetite has evaporated. This market is no longer built for singular, bold, early-stage breakthroughs. And where VC has pulled back, private equity is stepping in. 🐋 Historically focused on commercial-stage roll-ups, PE firms are now filling the gap VC left behind. Their structure allows them to provide deep capital and double down as builders, operators and strategic architects. Unlike most biotech VCs, PE firms: - Focus on operational value creation - Are experts in cash flow and capital structuring - Use non-dilutive financing, hybrid JVs, and NewCos - Invest in infrastructure-heavy plays like CDMOs, CROs, platforms. They're moving into territory VCs have vacated, increasingly building company portfolios from shelved pharma assets, launching holding companies that streamline overlapping R&D and buying control to fix execution and cost structures. Firms like GHO Capital Partners LLP, ARCHIMED and EW Healthcare Partners are assembling full-stack life science platforms with capital, talent and strategy under one roof. Others like Patient Square Capital and Permira are going further, hiring biotech leadership in-house and building internal venture studios with private equity rigor. This emerging model combines a cash-flow lens, a portfolio mindset and a bias for structure and scale. The PE playbook, now applied to biotech. But this model isn’t without risk. Drug development isn’t a factory, science fails, timelines (always) slip. Centralization can backfire. If PE leans too hard on financial engineering without understanding the regulatory, clinical or translational nuance, they risk destroying the very value they seek to unlock. But if done right, in 3–5 years, we’ll see a wave of derisked, asset-rich biotech companies backed by PE knocking on NYSE and Nasdaq doors. The volume could re-energize public markets and offer prime fishing grounds for large pharma looking to refill pipelines. I'm excited to see how this plays out. #BiotechFinance #PrivateEquity #DrugDevelopment #LifeSciences #VentureCapital #NewModels Artwork: Francesco Ciccolella

I am tremendously excited about the real-world impact of our latest publication on #AI #Biomarkers in Nature Medicine: https://lnkd.in/dv-7aS7Y Even in the US barely half of #lungcancer patients are tested for #EGFR mutations, for which targeted therapies readily exist. We have worked for many, many years now to try to overcome this gap with AI for H&E slides to offer patients a fast and cost-effective solution to get the right treatment. The point of this work is not only that we actually built it, but that Gabriele Campanella and Chad Vanderbilt organized a consortium and created the infrastructure for the first real-world, real-time deployment of a fine-tuned pathology foundation model for lung cancer biomarker detection. 𝙋𝙧𝙤𝙨𝙥𝙚𝙘𝙩𝙞𝙫𝙚𝙡𝙮!   𝐌𝐞𝐞𝐭 𝐄𝐀𝐆𝐋𝐄 (EGFR AI Genomic Lung Evaluation): ✅ 𝟎.𝟖𝟗 𝐀𝐔𝐂 in a 𝐩𝐫𝐨𝐬𝐩𝐞𝐜𝐭𝐢𝐯𝐞 silent trial with clinical-grade performance. 🌍 Generalizes 𝐚𝐜𝐫𝐨𝐬𝐬 𝐡𝐨𝐬𝐩𝐢𝐭𝐚𝐥𝐬 𝐚𝐧𝐝 𝐜𝐨𝐧𝐭𝐢𝐧𝐞𝐧𝐭𝐬 with robustness and reproducibility. 🔬 Validated on 𝐢𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐜𝐨𝐡𝐨𝐫𝐭𝐬, 𝐦𝐮𝐥𝐭𝐢𝐩𝐥𝐞 𝐢𝐧𝐬𝐭𝐢𝐭𝐮𝐭𝐢𝐨𝐧𝐬, 𝐚𝐧𝐝 𝐬𝐜𝐚𝐧𝐧𝐞𝐫𝐬. 🧪 𝟒𝟑% 𝐫𝐞𝐝𝐮𝐜𝐭𝐢𝐨𝐧 𝐢𝐧 𝐫𝐚𝐩𝐢𝐝 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫 𝐭𝐞𝐬𝐭𝐬, preserving biopsy tissue for full genomic profiling. ⚡ 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐬 𝐫𝐞𝐬𝐮𝐥𝐭𝐬 𝐢𝐧 𝐮𝐧𝐝𝐞𝐫 𝟏 𝐡𝐨𝐮𝐫, compared to 2–3 weeks for NGS. 🚀 A foundational step toward regulatory approval and 𝐀𝐈-𝐢𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐞𝐝 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐰𝐨𝐫𝐤𝐟𝐥𝐨𝐰𝐬.   We have worked on Computational Biomarkers in Pathology continuously for over a decade starting with AI for predicting SPOP in prostate cancer from H&E in 2015, but seeing everything come to fruition at such a scale in 2025 is very humbling. AI, when done right, can give real, tangible help to cancer patients. 𝑰𝒕 𝒊𝒔 𝒐𝒖𝒓 𝒓𝒆𝒔𝒑𝒐𝒏𝒔𝒊𝒃𝒊𝒍𝒊𝒕𝒚 𝒕𝒐 𝒎𝒂𝒌𝒆 𝒊𝒕 𝒂 𝒓𝒆𝒂𝒍𝒊𝒕𝒚! I am deeply grateful to everyone on this most amazing team: Gabriele Campanella, Neeraj Kumar, Ph.D., Swaraj Nanda, Siddharth Singi, Eugene Fluder, Ricky Kwan, Silke Mühlstedt, Nicole  Pfarr, Peter Schüffler, Ida Häggström, Noora Neittaanmäki, Levent Akyürek, Alina Basnet, Tamara Jamaspishvili, Michel Nasr, Matthew Croken, Fred Hirsch, Arielle Elkrief, Helena Yu, Orly Ardon, Greg Goldgof, Meera Hameed, Jane Houldsworth, Maria E. Arcila, Chad Vanderbilt #AI #ComputationalPathology #Biomarkers #AIinHealthcare #DigitalPathology #PrecisionMedicine #LungCancer #EGFR #NatureMedicine #FoundationModels #EAGLEModel #EAGLE #Oncology

AstraZeneca just made a $555M AI pact with a San Francisco biotech - no clinical programs. No approved drugs. Just ONE thing that made every boardroom take notice: AstraZeneca has been steadily expanding its AI footprint. In 2025 alone, it announced a $5.3B AI deal with CSPC and a $200M oncology partnership with Tempus and Pathos AI. And now they just made one of their boldest platform bets yet. AstraZeneca just signed a $555M partnership with Algen Biotechnologies, a San Francisco biotech with zero approved products. What did they see? A platform so powerful it could generate dozens of drug targets continuously. Algen's platform is called AlgenBrain. It combines AI with CRISPR-based functional genomics to map how genes regulate immune pathways. These aren't one-off discoveries. AlgenBrain is a discovery engine that can continuously generate new targets for immune-mediated diseases. That means multiple shots on goal, not just a single product. For a partnership with no clinical data, that's rare. But this wasn't a product bet. It was a platform bet. Under the deal, Algen identifies and validates new immunology targets while AstraZeneca gains exclusive rights to develop therapies against them. Total value up to $555M in upfront and milestone payments. What's most striking is the stage where this partnership begins: before any drug programs exist. Target identification is one of the least predictable phases of R&D. Platforms like Algen's can shorten that timeline, lower attrition, and strengthen first-in-class potential across multiple indications. Milestone-based payments align both sides on long-term success while limiting AstraZeneca's risk. Pharma companies are moving upstream. They're partnering with AI platforms to build continuous discovery capacity rather than buying late-stage assets. The next wave of biopharma M&A won't chase blockbusters, it'll chase the systems that create them. After working on 90+ deals over 25 years, I'm watching this trend accelerate faster than most realize. 3 takeaways if you're building in biotech: • Platform over product. Scalable discovery commands premium value. • Structure for milestones. Balance reward and risk through staged terms. • Secure early alliances. First access often defines long-term differentiation. And if you're investing, this deal redefines value. It's not just about late-stage efficacy data, it's about solving upstream bottlenecks.

Imagine gene therapy treatments costing $100,000 instead of $2 million per dose. A new review shows this isn't just wishful thinking – continuous bioprocessing could reduce manufacturing costs by up to 80%, potentially transforming patient access to these life-changing treatments. A exciting review paper by Lorek et al. reveals how the shift from traditional batch processing to continuous manufacturing may revolutionize gene therapy production. The innovation lies in running multiple production steps simultaneously with constant material flow, enabled by multi-column chromatography systems and advanced process analytic technology (PAT). What makes this particularly exciting is how continuous processing addresses the core challenges of gene therapy manufacturing. Traditional batch processing requires larger facilities, faces significant downtime between batches, and struggles with consistency. In contrast, continuous processing achieves higher productivity at a smaller scale while improving product quality – critical factors for reducing those astronomical million-dollar-plus treatment costs. The technology behind this transformation is fascinating. Multi-column chromatography systems now enable continuous capture and purification of viral vectors, improving productivity nearly threefold while maintaining yields above 82%. Even more impressive is the integration of real-time monitoring through process analytical technologies. These systems use in -line spectroscopic sensors, dynamic light scattering, and rapid analytics to track critical quality attributes in real-time, ensuring consistent product quality while dramatically reducing manufacturing time and costs. The implications for patient care are profound. By reducing facility footprint, increasing productivity, and improving product quality, continuous processing could help transform gene therapies from last-resort options into more widely accessible treatments. Early studies suggest manufacturing costs could drop by 60-80% compared to traditional batch processing – a game-changing reduction that could dramatically expand patient access. What excites me most is how these advances are converging with artificial intelligence and automation. Real-time monitoring systems coupled with advanced process controls are enabling unprecedented precision in manufacturing, ensuring every batch meets the highest quality standards while maximizing efficiency. We're witnessing a fundamental shift in how gene therapies are manufactured. The question isn't just about cost reduction – it's about reimagining production to make these transformative treatments accessible to everyone who needs them. What are your thoughts on these developments? How do you see these manufacturing innovations reshaping the future of genetic medicine? #GeneTherapy #Biotechnology #ContinuousProcessing #Healthcare #Innovation #PatientAccess

🧠 Nature Biotechnology just published its editorial of the most impactful advances in biotechnology in 2025. Among them, these are the ones I found most compelling: 1) In vivo cellular therapies Shifting away from ex vivo manufacturing toward in vivo reprogramming of immune cells, exemplified by targeted lipid nanoparticle delivery of mRNA to specific T-cell subsets for CAR-T–like therapies. This approach can reduce manufacturing complexity, cost, and reliance on chemotherapy. 2) Personalized cancer vaccines Early-phase clinical trials showed promising results for neoantigen-targeted cancer vaccines, reinforcing their potential as a durable therapeutic strategy rather than a transient trend. 3) Post-animal preclinical models Tumor-on-chip and organ-on-chip technologies gained prominence, aligning with regulatory moves (including FDA initiatives) to reduce animal testing while offering scalable. 4) Next-generation genome engineering Novel systems such as bridge recombinases and CRISPR-coupled retrotransposons enable precise, large-scale, and scar-free DNA insertions, excisions, and inversions, expanding the scope of genome editing. Which advance do you think will have the greatest clinical impact?

Drug deals help pharma giants move the needle 💉 The bio and pharma partnership landscape is intensifying – with Bristol-Myers Squibb and BioNTech’s partnership the latest in a flurry of activity in the space. Bristol-Myers Squibb has been extraordinarily active in forming strategic partnerships, particularly in cutting-edge therapeutic areas. Recent major deals include: AI and Technology Partnerships ↳Perpetual Medicines: $55 million upfront plus $55 million equity investment, with up to $3.5 billion in potential milestone payments for cell therapy development using prime editing technology ↳VantAI: Partnership for molecular glues development using generative AI, with potential for up to $674 million in research milestone payments ↳Terray Therapeutics: Multi-target collaboration leveraging the tNova platform for small molecule therapeutics discovery Broader Therapeutic Focus ↳BioArctic: $100 million upfront with up to $1.25 billion in milestone payments for Alzheimer's drug licensing ↳Scenic Biotech: Research collaboration utilizing Cell-Seq platform for drug target development This aggressive partnership strategy reflects Bristol-Myers Squibb's focus on "predictive science to reduce drug development costs and expedite treatment discovery", as the company transitions from legacy products to its growth portfolio, which now accounts for over half of its revenue. Broader Industry Trends The partnership intensity reflects broader market dynamics in the AI-derived biological drugs space, which has seen $2.9 billion in funding over the past two years as companies like Bristol-Myers Squibb seek to leverage AI for more efficient drug development. Based on recent partnership activity, six key therapeutic areas are driving the highest-value strategic alliances, with oncology leading the pack in terms of both deal size and frequency. 1. Oncology 2. AI-Powered Drug Discovery 3. Immunology 4. Neuroscience & CNS Disorders 5. Obesity & Metabolic Diseases 6. Genetic Therapeutics These therapeutic areas reflect broader market dynamics where AI integration has become the common denominator, enabling more efficient drug discovery across all categories. Increased partnership volume demonstrates how established pharma companies are securing access to next-generation immunotherapies through strategic alliances in addition to internal R&D and acquisitions. As the race for the oncology market intensifies, expect more deals across partnerships, investments, and M&A.

Amgen just announced a $600,000,000 investment into a new Science & Innovation Center at its Thousand Oaks HQ While NIH funding has slowed and life sciences real estate demand has softened, Amgen is doubling down on R&D infrastructure. Here’s what makes this a strategic play: • $600M to build a multidisciplinary center designed to accelerate next-gen therapeutics • Replacing an aging, unused building with a state-of-the-art facility (dubbed “Building 50”) • Positioned to attract and retain top talent by fostering collaboration + cutting-edge discovery • Adds momentum to Amgen’s broader U.S. footprint after its $900M Ohio expansion and $1B North Carolina manufacturing plant Why it matters: Pharma is quietly becoming one of the few life sciences players still expanding while many developers and investors pull back. By owning and upgrading its critical infrastructure, Amgen is hedging against market softness and betting on long-term scientific growth! Is this the start of a new wave of pharma-led life sciences real estate investment or will market oversupply slow the momentum? Full story → https://lnkd.in/gnFyNbFZ